A Call to Action: Addressing Diabetes Medication Safety

Similar documents
Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Glycemic control a matter of life and death

In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.

Long-Term Care Updates

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

A Guidance Statement from the American College of Physicians

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Study of hypoglycemia in elderly diabetes mellitus

Type 2 Diabetes Mellitus 2011

WHO Guidelines for Management of Diabetes in Low Resource Settings

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Comprehensive Diabetes Treatment

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

A collaborative approach to managing Diabetes in Long Term Care

Managing Diabetes and Hyperglycemia Safely in the Complex Hospital Setting

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Glucose Control and Prevention of Cardiovascular Disease

NOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada

Getting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Canadian Diabetes Association 2013

DIABETES MEASURES GROUP OVERVIEW

Hanyang University Guri Hospital Chang Beom Lee

Insulin Prior Authorization with optional Quantity Limit Program Summary

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

American Diabetes Association 2018 Guidelines Important Notable Points

Basal Insulin Drug Class Prior Authorization Protocol

Diabetes Quality Improvement Initiative

Initiating Injectable Therapy in Type 2 Diabetes

123 Are You Providing Evidence-Based Diabetes Care? - Martin

Diabetes Mellitus Type 2 Evidence-Based Drivers

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Practical Predictive Analytics. John Cuddeback, MD, PhD AMA IPPS November 11, 2016

Microvascular Disease in Type 1 Diabetes

Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness

DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL

Role of Academia In Achieving Targets in Diabetes Care

1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic

Vishwanath Pattan Endocrinology Wyoming Medical Center

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections

Type 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival

Diabetes Mellitus: A Cardiovascular Disease

The Many Faces of T2DM in Long-term Care Facilities

Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University

Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes

Diabetes Treatment Update

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

The Ever-Changing Approaches to Diabetes in Pregnancy

Correct Site Rotation

Balancing Glycemic Overtreatment and Undertreatment for Seniors: An Out of Range (OOR) Population Health Safety Measure

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Glucose Control: Does it lower CV risk?

Injecting Insulin into Out Patient Practice

Diabetic Nephropathy 2009

Update in Geriatrics: Choosing Wisely Primum Non Nocere

A Children s Bedtime Story

Moving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

DIABETES DEBATE - IS NEW BETTER?

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

APPENDIX American Diabetes Association. Published online at

DOI: /jemds/2014/2044 ORIGINAL ARTICLE

Glycemic Control Hitting the Sweet Spot During Inpatient Care

Case Study. Patient Profile. Baseline Report - Daily Patterns. Insights

Glucose and CV disease

Wayne Gravois, MD August 6, 2017

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Rational Goal-Setting and Management of Diabetes in the Elderly

Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

When and how to start insulin therapy in type 2 diabetes

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study)

Choosing a Diabetes Strategy Where to Start and Where to Go

Assessing the value of the Ambulatory Glucose Profile in clinical practice

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

What s New on the Horizon: Diabetes Medication Update

INCRETIN THERAPY ROUNDTABLE: Putting recommendations into practice. Program guide

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

DEMYSTIFYING INSULIN THERAPY

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

Transcription:

A Call to Action: Addressing Diabetes Medication Safety Evan M. Klass, M.D., F.A.C.P. Senior Associate Dean, Statewide Initiatives

Reducing ED visits for insulin induced hypoglycemia is a Healthy People 2020 goal!

Scope of the Problem 9.3% of the US population has DM (>90% type2) 7 th leading cause of death 14 million emergency department visits annually In 2011,thre were 4,841 practicing endocrinologists or 1/6,000 patients with Diabetes

ED Visits for Adverse Drug Events 2013-2014: 4 ED visits/1000 persons for ADE 27% of these resulted in hospital admission 34.5% of ER visits for ADE occurred in seniors (age >65) 5 Diabetes medications account (Insulin, metformin, glipizide, glyburide, glimepiride) were among the 15 most common causes of ED visits for ADEs Shebab N, Lovegrove M, et al. US emergency visits for outpatient adverse drug events, 2013-2014 JAMA 2016;314(20):2115-2125

How did we get here? Jean Pirart, 1978 Diabetes Care volume 1! Reported his personal observations of 4400 patients over years and correlated complications with his perceptions of glycemic control Before that there was no consensus on causality of complications

How did We get Here? Finger stick glucose monitoring HbA1c measurement New delivery systems- pumps and pens New and improved medications Heavy pharma engagement

How did We get Here? Great science- 2 landmark studies DCCT- 1993 UKPDS

Median HbA1c concentrations during DCCT, the training period between DCCT and EDIC, and EDIC. P < 0.001 for INT vs. David M. Nathan, and for the DCCT/EDIC Research Group Dia Care 2014;37:9-16 2014 by American Diabetes Association

How did We get Here? DCCT- proved that microvascular complications correlated with A1c in Type 1 UKPDS- demonstrated similar findings in Type 2 How low is low enough?

From: Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes JAMA Intern Med. 2016;176(7):969-978. doi:10.1001/jamainternmed.2016.2275

From: National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011 JAMA Intern Med. 2014;174(7):1116-1124. doi:10.1001/jamainternmed.2014.1824 Rates of Estimated Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries With Diabetes Mellitus, 1999 to 2010The circles and diamonds indicate observed values; the lines represent the smoothed trend over time.

Kaplan-Meier Curves for the Primary Outcome and Death from Any Cause The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559

Hazard Ratios for the Primary Outcome and Death from Any Cause in Prespecified Subgroups The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559

Addition of a Second Line Drug Before it s Time Metformin is the most important oral agent in the treatment of Type 2 Diabetes Every patient with Type 2 DM should be on metformin on the maximal tolerated dose consistent with compliance Use of metformin is safe if egfr is >30 and in the absence of advanced CHF, or COPD A recent study demonstrated that only 8.25 (1875/52544) had evidence of recommended use of metformin before beginning a second line agent¹ This is a huge problem- rapid up-migration to medications with high hypoglycemia risk! ¹Tseng Y, Steinberg G, et al. Antihyperglycemic medications: A claims based estimate of first-line therapy use prior to initialization of second line medications. Diabetes Care 2017; 40:1500-1505

Number of Cases and Estimates of Precipitating Factors Identified in ED Visits for IHEs (United States, 2007-2011) a

Diabetes in Seniors 25% of those over 65 have Diabetes Multiple co-morbidities High rate of cognitive impairment Polypharmacy Seniors over 80 have twice the risk of ED visits for hypoglycemia and 5x risk of hospital admission

Consequences of Hypoglycemia Increased risk of dementia Falls Fall-related fractures C-V events Diminished QOL Increased mortality

ADA HbA1c Targets- 2017 Non-pregnant adults- <7% Selected patients, or those treated by lifestyle modification or metformin only <6.5% For patients with severe hypoglycemia or advanced complications <8% For many seniors, relax targets to prevent symptomatic hypoglycemia

Using Admission A1c to Guide Discharge Planning A1c<8%- No meds-begin metformin. On meds, continue current regimen A1c 8-9- No meds-begin metformin. On meds, increase meds, add another agent or consider basal insulin at 50% of hospital dose A1c>9 no symptoms- No meds-begin metformin and 2nd agent. On meds-increase doses and consider addition of basal insulin at 80% of inpatient level A1c>9 with symptoms- Consider metformin and add basal/bolus therapy

Summary Hypoglycemia has surpassed hyperglycemia as a cause of ER visits and hospitalization A1c targets might have been overly aggressive in many patients Patient and prescriber errors are major contributors Hypoglycemia risk is exaggerated in the elderly- and consequences may be severe